Compare Marathon Petroleum Corp (MPC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Recursion Pharmaceuticals Inc — how do they compare? Marathon Petroleum Corp trades at $318.36 (market cap $92.05B), while Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B). The key difference: Marathon Petroleum Corp is far larger — about 60.2× Recursion Pharmaceuticals Inc's market cap, and Marathon Petroleum Corp pays a 1.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MPC | RXRX | |
|---|---|---|
Market Cap | $92.05B | $1.53B |
Sector | Energy | Health |
52-Week High | $315.31 | $6.79 |
52-Week Low | $158.59 | $2.84 |
Enterprise Value | $124.23B | $946.50M |
Dividend Yield | 1.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
